Value proposition

A shift in cancer treatment methodology makes a world of difference.

A shift in cancer treatment methodology makes a world of difference.

Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA).

Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme.

Biotechnology, cancer, cell dormancy, first-in-class, biopharmaceutical, precision oncology, cancer persistence, Spin-off, Targeted therapy, and TET2